Grufity logoGrufity logo

SRNE

1.26USD+0.03(+2.44%)Market Closed

Sorrento Therapeutics Inc

Market Summary

USD1.26+0.03Market Closed
2.44%

SRNE Alerts

SRNE Stock Price

RSI Chart

Valuation

Market Cap

728.9M

Price/Earnings

-1.39

Price/Sales

13.26

Price/Cashflow

-2.28

MarketCap/EBT

-1.31

Price/Sales

Profitability

EBT Margin

-1013.95%

Return on Equity

-396.74%

Return on Assets

-82.86%

Fundamentals

Revenue

Revenue (TTM)

60.3M

Revenue Y/Y

44.25%

Revenue Q/Q

51.82%

Earnings

Earnings (TTM)

-493.6M

Earnings Y/Y

25.23%

Earnings Q/Q

59.05%

Price Action

52 Week Range

6.53
(Low)(High)

Last 7 days

-6.7%

Last 30 days

-14.9%

Last 90 days

-37.3%

Trailing 12 Months

-77.1%

Financial Health

Current Ratio

1.35

Investor Care

Shares Dilution (1Y)

54.04%

Diluted EPS (TTM)

-1.33

Peers (Alternatives to Sorrento Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
16.6B
3.3B
7.75% 24.76%
17.56
5
22.05% 63.88%
MID-CAP
6.1B
1.9B
40.44% -42.46%
-8.33
3.16
13.25% 11.39%
5.4B
1.6B
2.23% 5.52%
19.63
3.44
30.66% 87.25%
5.2B
5.4B
-28.76% -64.60%
18.72
0.96
8.57% 14.42%
3.8B
243.2M
-1.96% -51.31%
-24.67
15.19
75.89% -25.00%
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
955.6M
3.3M
2.29% -33.20%
-21.05
291.16
-26.92% -26.56%
728.9M
60.3M
-14.86% -77.13%
-1.39
13.26
17.51% -38.87%
335.1M
75.9M
15.24% -52.63%
-3.66
4.15
9.61% 123.40%
19.1M
-
3.68% -62.86%
-2.32
-
- 22.78%
3.4M
-
1.85% -88.32%
-0.06
155.91
- -67.16%

Financials for Sorrento Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue9.7%6055575351
  S&GA Expenses-1.1%196198197183
Earnings Before Taxes5.0%-529.44-557.51-504.25-462.65-363.81
Net Income5.8%-493.57-523.79-471.65-428.32-355.41
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-2.6%616632856695753
  Current Assets-9.7%177196331173201
    Cash Equivalents0.5%71701123740
  Inventory-13.2%18211485
  Net PPE2.6%4443424146
  Goodwill-1.5%8081808053
Liabilities-2.2%485496629617621
  Current Liabilities39.0%202145204139175
    LT Debt, Current123.1%5324573227
    LT Debt, Non Current-78.6%18839611183
Shareholder's Equity-1.4%13013222779132
  Retained Earnings-5.4%-1,735.75-1,646.18-1,427.42-1,386.60-1,242.19
  Additional Paid-In Capital7.2%1,8271,7041,5141,422-
Accumulated Depreciation-43----
Shares Outstanding7.3%468436375315303
Minority Interest-143.9%-1.644-0.34-0.62-0.17
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations6.9%-297.66-319.60-317.12-281.82-250.55
  Share Based Compensation-3.1%8083879086
Cashflow From Investing-110.5%-25.69-12.20688071
Cashflow From Financing9.6%35732631918199

Risks

What is the probability of a big loss on SRNE?

100%


Probability that Sorrento Therapeutics stock will be more than 20% underwater in next one year

100%


Probability that Sorrento Therapeutics stock will be more than 30% underwater in next one year.

100%


Probability that Sorrento Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SRNE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Sorrento Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on SRNE

-13.7%


10-Year Cumulative Returns

-22.9%


7-Year Cumulative Returns

-11.3%


5-Year Cumulative Returns

-30.4%


3-Year Cumulative Returns

What are the long-term rolling returns for SRNE?

FIve years rolling returns for Sorrento Therapeutics.

Which funds bought or sold SRNE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
IHT Wealth Management, LLC
-
-
-8,000
27,000
-%
2022-11-22
B. Riley Wealth Advisors, Inc.
NEW
-
20,000
20,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-75,000
761,000
-%
2022-11-17
M&T Bank Corp
-
-
16,000
23,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
ADDED
1,299.77
44,000
48,000
-%
2022-11-16
GLENMEDE TRUST CO NA
NEW
-
18,000
18,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
Laurel Wealth Advisors LLC
SOLD OFF
-100
-1,000
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
-15,000
52,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
937.98
1,269,640
1,448,270
-%

1–10 of 45

Latest Funds Activity

Are funds buying SRNE calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own SRNE

Sorrento Therapeutics News

InvestorsObserver

Should You Accumulate Sorrento Therapeutics Inc (SRNE) Stock Wednesday?.4 days ago

SRNE Fair Value

Recent SEC filings of Sorrento Therapeutics

View All Filings
Date Filed Form Type Document
Nov 23, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 18, 2022
8-K
Current Report
Nov 17, 2022
SC 13D
13D - Major Acquisition
Nov 15, 2022
3
Insider Trading
Nov 15, 2022
4
Insider Trading
Nov 08, 2022
10-Q
Quarterly Report
Nov 01, 2022
DEFA14A
DEFA14A
Nov 01, 2022
DEF 14A
DEF 14A
Sep 29, 2022
8-K
Current Report

Latest Insider Trading transactions for SRNE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-09-07
Ji Henry
BOUGHT
179,349
2.0177
88,888
See Remarks
2022-09-06
Ji Henry
BOUGHT
108,882
1.9599
55,555
See Remarks
2022-09-02
Ji Henry
ACQUIRED
-
-
2,500,000
See Remarks
2022-08-26
Ji Henry
BOUGHT
70,332.6
2.11
33,333
See Remarks
2022-08-25
Ji Henry
BOUGHT
45,768.4
2.0596
22,222
See Remarks
2022-06-14
Ji Henry
BOUGHT
13,999
1.3999
10,000
See Remarks
2021-12-27
Janda Kim
ACQUIRED
12,000
4
3,000
-
2021-12-27
Janda Kim
SOLD
-17,640
5.88
-3,000
-
2021-09-29
Ji Henry
ACQUIRED
40,000
4
10,000
See Remarks
2021-09-27
Janda Kim
ACQUIRED
89,264.5
2.10743
42,357
-

1–10 of 20

Henry H. Ji
800
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

SRNE Income Statement

2022-09-30
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Revenues$ 17,400$ 12,062$ 47,245$ 39,828
Operating costs and expenses:    
Research and development67,98949,448180,182147,787
Acquired in-process research and development 11,12512,27223,608
Selling, general and administrative50,15948,489142,873142,176
Intangible amortization1,1271,0003,1963,105
(Decrease) increase on contingent consideration(700) (67,100)100
Loss on impairment of intangible assets  90,780 
Total operating costs and expenses126,843113,449381,933326,670
Loss from operations(109,443)(101,387)(334,688)(286,842)
Gain (loss) on derivative liabilities500(1,800)5,300100
(Loss) gain on marketable investments(16,084)(13,483)(43,042)17,047
Gain (loss) on debt extinguishment33,433 27,701(6,695)
Gain (loss) on foreign currency exchange610(300)445(841)
Interest expense, net(792)(2,900)(6,355)(7,282)
Other income (loss)7497(609)53
Loss before income tax(91,702)(119,773)(351,248)(284,460)
Income tax (expense) benefit(1,015)386(602)(461)
Gain (loss) on equity method investments621643(277)
Net loss(90,625)(119,995)(350,643)(284,276)
Net loss attributable to noncontrolling interests(1,049)(192)(1,492)(368)
Net loss attributable to Sorrento$ (89,576)$ (119,803)$ (349,151)$ (283,908)
Net loss per share - basic per share attributable to Sorrento (USD per share)$ (0.20)$ (0.40)$ (0.88)$ (0.98)
Net loss per share - diluted per share attributable to Sorrento (USD per share)$ (0.20)$ (0.40)$ (0.88)$ (0.98)
Weighted-average shares used during period - basic shares attributable to Sorrento (in shares)451,621299,276397,601290,029
Weighted-average shares used during period - diluted shares attributable to Sorrento (in shares)451,621299,276397,601290,029
Product    
Revenues:    
Revenues$ 13,649$ 7,562$ 32,231$ 22,439
Operating costs and expenses:    
Cost of products sold and services7,2831,17215,6382,549
Service    
Revenues:    
Revenues3,7514,50015,01417,389
Operating costs and expenses:    
Cost of products sold and services$ 985$ 2,215$ 4,092$ 7,345

SRNE Balance Sheet

2022-09-30
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 70,686$ 36,665
Marketable investments47,17590,217
Accounts receivables, net24,19018,715
Inventory17,9618,106
Prepaid expenses7,93711,804
Other current assets9,0087,482
Total current assets176,957172,989
Property and equipment, net43,63441,325
Operating lease right-of-use assets85,26185,173
Intangibles, net171,440259,705
Goodwill80,19979,525
Equity investments55,60551,271
Other assets, net2,5184,830
Total assets615,614694,818
Current liabilities:  
Accounts payable38,39127,414
Accrued payroll and related benefits29,19721,503
Accrued expenses59,76437,975
Current portion of deferred revenue2811,108
Current portion of operating lease liabilities13,37311,539
Current portion of contingent consideration397397
Acquisition consideration7,6707,537
Current portion of debt52,90731,980
Total current liabilities201,980139,453
Long-term debt, net of discount17,800110,627
Deferred tax liabilities, net1,7442,426
Deferred revenue117,224118,942
Derivative liabilities 35,700
Operating lease liabilities84,13383,431
Contingent consideration57,249124,349
Other long-term liabilities5,2781,761
Total liabilities485,408616,689
Commitments and contingencies (See Note 10)
Sorrento Therapeutics, Inc. equity  
Common stock, $0.0001 par value 750,000,000 shares authorized and 468,290,927 and 314,573,225 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively4732
Additional paid-in capital1,916,7941,513,758
Accumulated other comprehensive income2261,026
Accumulated deficit(1,735,755)(1,386,604)
Treasury stock, 7,568,182 shares at cost at September 30, 2022, and December 31, 2021(49,464)(49,464)
Total Sorrento Therapeutics, Inc. stockholders’ equity131,84878,748
Noncontrolling interests(1,642)(619)
Total equity130,20678,129
Total liabilities and stockholders’ equity$ 615,614$ 694,818